文献类型：期刊文献

中文题名：Harvest of functional mesenchymal stem cells derived from in vivo osteo-organoids

作者：Shunshu Deng[1,2,3];Fuwei Zhu[1,2,3];Kai Dai[1,2,3,4];Jing Wang[1,3,4];Changsheng Liu[2,3,4,5]

机构：[1]State Key Laboratory of Bioreactor Engineering,East China University of Science and Technology,Shanghai,China;[2]Key Laboratory for Ultrafine Materials of the Ministry of Education,East China University of Science and Technology,Shanghai,China;[3]Engineering Research Center for Biomedical Materials of the Ministry of Education,East China University of Science and Technology,Shanghai,China;[4]Frontiers Science Center for Materiobiology and Dynamic Chemistry,East China University of Science and Technology,Shanghai,China;[5]Shanghai University,Shanghai,China

年份：2023

卷号：4

期号：4

起止页码：270

中文期刊名：Biomaterials Translational

外文期刊名：生物材料转化电子杂志（英文）

基金：the Basic Science Center Program of National Natural Science Foundation of China,No.T2288102;the Key Program of the National Natural Science Foundation of China,No.32230059;the Foundation of Frontiers Science Center for Materiobiology and Dynamic Chemistry,No.JKVD1211002;the Wego Project of Chinese Academy of Sciences,No.(2020)005;the National Natural Science Foundation of China,No.32301123;the China Postdoctoral Science Foundation,No.2022M721147;the Project of National Facility for Translational Medicine(Shanghai),No.TMSK-2021-134.

语种：英文

中文关键词：anti-replicative senescence;in vivo osteo-organoid;mesenchymal stem cell;recombinant human bone morphogenetic protein 2;stem cell therapy

摘要：Bone marrow-derived mesenchymal stem cells(BM-MSCs)play a crucial role in stem cell therapy and are extensively used in regenerative medicine research.However,current methods for harvesting BM-MSCs present challenges,including a low yield of primary cells,long time of in vitro expansion,and diminished differentiation capability after passaging.Meanwhile mesenchymal stem cells(MSCs)recovered from cell banks also face issues like toxic effects of cryopreservation media.In this study,we provide a detailed protocol for the isolation and evaluation of MSCs derived from in vivo osteo-organoids,presenting an alternative to autologous MSCs.We used recombinant human bone morphogenetic protein 2-loaded gelatin sponge scaffolds to construct in vivo osteo-organoids,which were stable sources of MSCs with large quantity,high purity,and strong stemness.Compared with protocols using bone marrow,our protocol can obtain large numbers of high-purity MSCs in a shorter time(6 days vs.12 days for obtaining passage 1 MSCs)while maintaining higher stemness.Notably,we found that the in vivo osteo-organoid-derived MSCs exhibited stronger anti-replicative senescence capacity during passage and amplification,compared to BM-MSCs.The use of osteo-organoid-derived MSCs addresses the conflict between the limitations of autologous cells and the risks associated with allogeneic sources in stem cell transplantation.Consequently,our protocol emerges as a superior alternative for both stem cell research and tissue engineering.